EX-23.2 5 h08601a2exv23w2.txt CONSENT OF KPMG LLP, SEATTLE, WASHINGTON EXHIBIT 23.2 INDEPENDENT AUDITORS' CONSENT The Board of Directors Encysive Pharmaceuticals, Inc. We consent to the use of our report on the financial statements of ICOS - Texas Biotechnology, L.P. (a development stage limited partnership) incorporated by reference herein. Our report on the aforementioned financial statements of ICOS - Texas Biotechnology, L.P. dated January 30, 2003 contains an explanatory paragraph that states that ICOS - Texas Biotechnology, L.P. has experienced recurring losses from operations and has a partners' deficit which raise substantial doubt about its ability to continue as a going concern. The ICOS - Texas Biotechnology, L.P. financial statements do not include any adjustments that might result from the outcome of that uncertainty. /s/ KPMG LLP Seattle, Washington October 21, 2003